Claims for Patent: 8,742,076
✉ Email this page to a colleague
Summary for Patent: 8,742,076
Title: | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
Abstract: | The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D).sub.p I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders. |
Inventor(s): | Cohen; Robert L. (San Mateo, CA), Ha; Edward HyungSuk (San Francisco, CA), Reynolds; Mark E. (Millbrae, CA) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 12/865,354 |
Patent Claims: | 1. An antibody-drug conjugate compound selected from the structures: ##STR00082## wherein p is 1, 2, 3, 4, 5, 6, 7, or 8; and Ab is an antibody which binds to one or more
tumor-associated antigens or cell-surface receptors selected from (1)-(36): (1) BMPR1B (bone morphogenetic protein receptor-type IB), (2) E16 (LAT1, SLC7A5), (3) STEAP1 (six transmembrane epithelial antigen of prostate), (4) 0772P (CA125, MUC16), (5) MPF
(MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin), (6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b), (7) Sema 5b (FLJ10372, KIAA1445, Mm.42015,
SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B), (8) PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA
2700050C12 gene), (9) ETBR (Endothelin type B receptor), (10) MSG783 (RNF124, hypothetical protein FLJ20315), (11) STEAP2 (HGNC.sub.--8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1,
six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein), (12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4), (13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1,
teratocarcinoma-derived growth factor), (14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792), (15) CD79b (CD79B, CD79.beta., IGb (immunoglobulin-associated beta), B29), (16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain
containing phosphatase anchor protein 1a), SPAP1B, SPAP1C), (17) HER2, (18) NCA, (19) MDP, (20) IL20R.alpha., (21) Brevican, (22) EphB2R, (23) ASLG659, (24) PSCA, (25) GEDA, (26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3), (27) CD22
(B-cell receptor CD22-B isoform), (28) CD79a (CD79A, CD79.alpha., immunoglobulin-associated alpha), (29) CXCR5 (Burkitt's lymphoma receptor 1), (30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen)), (31) P2X5 (Purinergic receptor P2X
ligand-gated ion channel 5), (32) CD72 (B-cell differentiation antigen CD72, Lyb-2), (33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family), (34) FcRH1 (Fc receptor-like protein 1), (35) IRTA2
(Immunoglobulin superfamily receptor translocation associated 2), and (36) TENB2 (putative transmembrane proteoglycan).
2. The antibody-drug conjugate compound of claim 1 wherein Ab is a cysteine-engineered antibody. 3. The antibody-drug conjugate compound of claim 1 wherein Ab is an antibody which binds to an ErbB receptor. 4. The antibody-drug conjugate of claim 3 wherein Ab is trastuzumab. 5. The antibody-drug conjugate compound of claim 1 wherein p is 1, 2, 3, or 4. 6. A pharmaceutical composition comprising the antibody-drug conjugate compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or excipient. 7. The pharmaceutical composition of claim 6 further comprising a therapeutically effective amount of a chemotherapeutic agent. 8. An article of manufacture comprising an antibody-drug conjugate compound of claim 1; a container; and a package insert or label indicating that the compound can be used to treat cancer. |
Details for Patent 8,742,076
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.